Viking Therapeutics's total assets for Q1 2026 were $608.24M, a decrease of -15.02% from the previous quarter. VKTX total liabilities were $106.33M for the fiscal quarter, a 38.68% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.